

Chemoimmunotherapy treatment strategies on a mathematical model of cancer evolution

Mathematical model of cancer with chemoimmunotherapy

TECNOLÓGICO

NACIONAL DE MÉXICO

The mathematical model of cancer chemoimmunotherapy presented by de Pillis et al. [1] describes the dynamics between the population of tumor cells T(t), the NK cells N(t), the effector cells L(t), the circulating lymphocytes C(t), the concentration of the chemotherapy drug (doxorubicin) M(t) and the IL-2 (interleukin-2) I(t).

$$\dot{T} = aT(1-bT) - cNT - DT - K_T(1-e^{-\delta_T M})T,$$
 (1)

$$\dot{N} = f\left(\frac{e}{f}C - N\right) - pNT + \frac{p_N NI}{g_N + I} - K_N(1 - e^{-\delta_N M})N,\tag{2}$$

$$\dot{L} = \frac{\theta m L}{\theta + I} + j \frac{T}{k + T} L - qLT + (r_1 N + r_2 C)T - \frac{uL^2 CI}{\kappa + I}$$
(3)

$$-K_L(1-e^{-\delta_L M})L+\frac{p_I LI}{g_I+I}+v_L,$$

$$\dot{C} = \beta \left(\frac{\alpha}{\beta} - C \right) - K_C (1 - e^{-\delta_C M}) C, \tag{4}$$

$$\dot{M} = -\gamma M + v_M, \tag{5}$$

$$\dot{I} = -\mu_I I + \phi C + \frac{\omega L I}{\zeta + I} + v_I,$$
(6)

where $D = rac{dL^l}{sT^l + L^l}$.

The dynamics of the system (1)-(6) is located in the non-negative ortant:

 $\mathbf{R}_{+,0}^6 = \{T \ge 0, N \ge 0, L \ge 0, C \ge 0, M \ge 0, I \ge 0\}.$

Assumption

If a solution describing the growth of a cell population goes below the value of 1 cell, then it is possible to assume the complete eradication of such population [2,4].

References

[1] de Pillis, Lisette, et al. "Mathematical model creation for cancer chemoimmunotherapy." Computational and Mathematical Methods in *Medicine* 10.3 (2009): 165-184.

[2] Valle Paul A., Coria Luis N., Plata Corina. Personalized Immunotherapy Treatment Strategies for a Dynamical System of Chronic Myelogenous Leukemia. Cancers 13.9 (2021): 22 pages.

[3] Khalil, H. K., Nonlinear systems, Prentice-Hall, 3rd edn., 2002

[4] Valle, Paul A., et al. "CAR-T Cell Therapy for the Treatment of ALL: Eradication Conditions and In Silico Experimentation." *Hemato* 2.3 (2021): 441-462.

Acknowledgments

This work was supported by TecNM with project number 9951.21-P titled "Computational modelling and in silico experimentation applied to the analysis and control of biological systems" (Modelizado computacional y experimentos in silico aplicados al análisis y control de sistemas biológicos).

Sandra M. López^{1*}, Yolocuauhtli Salazar², Paul A. Valle¹.

¹Postgraduate Program in Engineering Sciencies, BioMath Research Group, Tecnológico Nacional de México/ IT Tijuana, México. ²Postgraduate Program in Engineering, Tecnológico Nacional de México/ IT Durango, México. *sandra.lopez201@tectijuana.edu.mx

Asymptotic stability at the tumor-free equilibrium point

We apply the Lyapunov's direct method [3] to establish sufficient conditions to ensure the elimination of the tumor in the chemoimmunotherapy system (1)-(6). For this, we propose the candidate Lyapunov function $h_6 = T$ and determine the Lie derivative as follows:

$$L_{f}h_{6} = \left[a - abT - cN - \frac{dL^{l}}{sT^{l} + L^{l}} - K_{T}(1 - e^{-\delta_{T}M})\right]T.$$

In addition, it is observed that $L_f h_6$ is negative definite, i.e., $L_f h_6 \leq 0$, if the following condition is fulfilled:

$$a-abT-cN-\frac{dL^{\iota}}{sT^{\iota}+L^{\iota}}-K_{T}\left(1-e^{-\delta_{T}M}\right)<0.$$

Considering the following statements about the boundaries of the populations of lymphocytes, NK and T cells, it is possible to obtain the solution of the inequality

$$\begin{split} C_{inf} &\geq C_{inf^{-}} = \frac{\alpha}{\beta + K_{C}}, & C_{sup} \leq C_{sup^{+}} = \frac{\alpha}{\beta}, \\ N_{inf} &\geq N_{inf^{-}} = \frac{eC_{inf^{-}}}{f + pb^{-1} + K_{N}}, & N_{sup} \leq N_{sup^{+}} = \frac{eC_{sup^{+}}}{f - p_{N}}, \\ L_{inf} &\geq L_{inf^{-}} = \sqrt{\frac{\nu_{L}}{\sigma_{6}} + \frac{\sigma_{7}^{2}}{4\sigma_{6}^{2}} - \frac{\sigma_{7}}{2\sigma_{6}}}, & \sigma_{6} = uC_{sup^{+}}, \\ \sigma_{7} &= qb^{-1} + K_{L}. \end{split}$$

and accordingly, the next negative upper limit is defined for $L_f h_6$

$$L_{f}h_{6} \leq \left[a - cN_{inf^{-}} - \frac{dL_{inf^{-}}^{l}}{sb^{-l} + L_{inf^{-}}^{l}} - K_{T}(1 - e^{-\delta_{T}M_{inf}})\right]T \leq 0.$$

One can solve the following inequality with respect to the two treatment parameters and get the next two cases:

$$a - cN_{inf^{-}} - \frac{dL_{inf^{-}}^{l}}{sb^{-l} + L_{inf^{-}}^{l}} - K_{T}(1 - e^{-\delta_{T}M_{inf}}) < 0.$$

Case 1: With respect to chemotherapy treatment v_M :

$$\nu_{M} = M_{inf} > \frac{1}{\delta_{T}} \ln \left[-1 + \frac{a}{K_{T}} - \frac{cN_{inf}}{K_{T}} - \frac{dL_{inf}^{l}}{K_{T} \left(sb^{-l} + L_{inf}^{l} \right)} \right],$$
(7)

By replacing the value of the parameters, we obtain

$$v_M > v_{M_{inf}} = 0.3556 \ \frac{mg}{l \times day}.$$

Case 2: With respect to immunotherapy treatment v_L :

$$\nu_{L} > \frac{u\alpha}{\beta} \left[\sqrt[l]{\frac{sb^{-l}(f+pb^{-1}+K_{N})(\beta+K_{C})[a-K_{T}(1-e^{-\delta_{T}\nu_{M}})]-sb^{-l}ce\alpha}{(f+pb^{-1}+K_{N})(\beta+K_{C})[d-a-K_{T}(1-e^{-\delta_{T}\nu_{M}})]+ce\alpha}} \right]^{2}$$
(8)

$$+ \left[\sqrt[l]{\frac{sb^{-l}(f+pb^{-1}+K_N)(\beta+K_C)[a-K_T(1-e^{-\delta_T v_M})]-sb^{-l}ce\alpha}{(f+pb^{-1}+K_N)(\beta+K_C)[d-a-K_T(1-e^{-\delta_T v_M})]+ce\alpha}} \right] (qb^{-1}+K_L),$$

By replacing the value of the parameters, we obtain

$$v_L > v_{L_{inf}} = 8.5455 \times 10^8 \frac{cells}{l \times day}$$



